Is SLDB or DNLI more profitable?

Denali Therapeutics' return on equity of -52.20% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -73.42% -61.13% Denali Therapeutics N/A -52.20% -43.86%

Does the media prefer SLDB or DNLI?

In the previous week, Denali Therapeutics had 9 more articles in the media than Solid Biosciences. MarketBeat recorded 11 mentions for Denali Therapeutics and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.84 beat Denali Therapeutics' score of 0.78 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NAMS or SLDB?

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 2 mentions for Solid Biosciences. NewAmsterdam Pharma's average media sentiment score of 1.29 beat Solid Biosciences' score of 0.84 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, DYN or SLDB?

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A Solid Biosciences N/A N/A -$174.32M -$1.95 N/A

Is DYN or SLDB more profitable?

Dyne Therapeutics' return on equity of -58.28% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -58.28% -46.77% Solid Biosciences N/A -73.42% -61.13%

Does the media prefer DYN or SLDB?

In the previous week, Dyne Therapeutics had 8 more articles in the media than Solid Biosciences. MarketBeat recorded 10 mentions for Dyne Therapeutics and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.84 beat Dyne Therapeutics' score of 0.52 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, TLX or SLDB?

Telix Pharmaceuticals has higher revenue and earnings than Solid Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.65 -$7.12M N/A N/A Solid Biosciences N/A N/A -$174.32M -$1.95 N/A

Is TLX or SLDB more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Solid Biosciences N/A -73.42% -61.13%

Does the media prefer TLX or SLDB?

In the previous week, Telix Pharmaceuticals had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.84 beat Telix Pharmaceuticals' score of 0.47 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, GPCR or SLDB?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A Solid Biosciences N/A N/A -$174.32M -$1.95 N/A

Is GPCR or SLDB more profitable?

Structure Therapeutics' return on equity of -24.91% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -24.91% -23.67% Solid Biosciences N/A -73.42% -61.13%

Does the media favor GPCR or SLDB?

In the previous week, Structure Therapeutics and Structure Therapeutics both had 2 articles in the media. Structure Therapeutics' average media sentiment score of 1.61 beat Solid Biosciences' score of 0.84 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Solid Biosciences (SLDB) Competitors

$9.89 +0.17 (+1.79%)

As of 12:20 PM Eastern

Compare

SLDB vs. DNLI, NAMS, DYN, TLX, and GPCR

Should you buy Solid Biosciences stock or one of its competitors? MarketBeat compares Solid Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Solid Biosciences include Denali Therapeutics (DNLI), NewAmsterdam Pharma (NAMS), Dyne Therapeutics (DYN), Telix Pharmaceuticals (TLX), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

How does Solid Biosciences compare to Denali Therapeutics?

Solid Biosciences (NASDAQ:SLDB) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Solid Biosciences has a beta of 2.36, indicating that its share price is 136% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Denali Therapeutics' return on equity of -52.20% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Denali Therapeutics	N/A	-52.20%	-43.86%

Solid Biosciences has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Denali Therapeutics	$330.53M	10.73	-$512.54M	-$2.88	N/A

In the previous week, Denali Therapeutics had 9 more articles in the media than Solid Biosciences. MarketBeat recorded 11 mentions for Denali Therapeutics and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.84 beat Denali Therapeutics' score of 0.78 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences presently has a consensus target price of $17.00, indicating a potential upside of 73.29%. Denali Therapeutics has a consensus target price of $34.75, indicating a potential upside of 55.56%. Given Solid Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Solid Biosciences is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81

Summary

Solid Biosciences and Denali Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Solid Biosciences compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Solid Biosciences (NASDAQ:SLDB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

NewAmsterdam Pharma presently has a consensus price target of $49.00, indicating a potential upside of 44.79%. Solid Biosciences has a consensus price target of $17.00, indicating a potential upside of 73.29%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Solid Biosciences is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

NewAmsterdam Pharma has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market.

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 2.7% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Solid Biosciences has lower revenue, but higher earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	175.83	-$203.82M	-$1.79	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

Solid Biosciences has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Solid Biosciences	N/A	-73.42%	-61.13%

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 2 mentions for Solid Biosciences. NewAmsterdam Pharma's average media sentiment score of 1.29 beat Solid Biosciences' score of 0.84 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NewAmsterdam Pharma beats Solid Biosciences on 8 of the 15 factors compared between the two stocks.

How does Solid Biosciences compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Solid Biosciences (NASDAQ:SLDB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

Dyne Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.36, indicating that its share price is 136% more volatile than the broader market.

In the previous week, Dyne Therapeutics had 8 more articles in the media than Solid Biosciences. MarketBeat recorded 10 mentions for Dyne Therapeutics and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.84 beat Dyne Therapeutics' score of 0.52 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by insiders. Comparatively, 2.7% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dyne Therapeutics' return on equity of -58.28% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Solid Biosciences	N/A	-73.42%	-61.13%

Dyne Therapeutics presently has a consensus target price of $34.17, suggesting a potential upside of 43.88%. Solid Biosciences has a consensus target price of $17.00, suggesting a potential upside of 73.29%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Solid Biosciences is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Solid Biosciences beats Dyne Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Solid Biosciences compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Solid Biosciences (NASDAQ:SLDB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Telix Pharmaceuticals presently has a consensus target price of $21.00, indicating a potential upside of 90.58%. Solid Biosciences has a consensus target price of $17.00, indicating a potential upside of 73.29%. Given Telix Pharmaceuticals' higher possible upside, equities research analysts plainly believe Telix Pharmaceuticals is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Telix Pharmaceuticals' return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Solid Biosciences	N/A	-73.42%	-61.13%

81.5% of Solid Biosciences shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Telix Pharmaceuticals has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.36, indicating that its share price is 136% more volatile than the broader market.

Telix Pharmaceuticals has higher revenue and earnings than Solid Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.65	-$7.12M	N/A	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

In the previous week, Telix Pharmaceuticals had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.84 beat Telix Pharmaceuticals' score of 0.47 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Telix Pharmaceuticals and Solid Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Solid Biosciences compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Solid Biosciences (NASDAQ:SLDB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Structure Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

Structure Therapeutics' return on equity of -24.91% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Solid Biosciences	N/A	-73.42%	-61.13%

Structure Therapeutics presently has a consensus price target of $110.55, suggesting a potential upside of 118.79%. Solid Biosciences has a consensus price target of $17.00, suggesting a potential upside of 73.29%. Given Structure Therapeutics' higher possible upside, equities analysts clearly believe Structure Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by insiders. Comparatively, 2.7% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Structure Therapeutics has a beta of -1.5, meaning that its stock price is 250% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.36, meaning that its stock price is 136% more volatile than the broader market.

In the previous week, Structure Therapeutics and Structure Therapeutics both had 2 articles in the media. Structure Therapeutics' average media sentiment score of 1.61 beat Solid Biosciences' score of 0.84 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Structure Therapeutics beats Solid Biosciences on 10 of the 13 factors compared between the two stocks.

Get Solid Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLDB vs. The Competition

Export

Metric	Solid Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$965.79M	$3.64B	$6.74B	$12.51B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-5.03	21.01	26.90	24.39
Price / Sales	N/A	314.09	587.69	117.46
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	4.30	8.50	10.92	6.33
Net Income	-$174.32M	$23.83M	$3.58B	$330.66M
7 Day Performance	-12.02%	-3.45%	-2.25%	-0.84%
1 Month Performance	37.39%	6.33%	3.08%	-0.26%
1 Year Performance	79.34%	48.44%	26.23%	19.99%

Solid Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLDB Solid Biosciences	2.6372 of 5 stars	$9.89 +1.8%	$17.00 +71.8%	+84.8%	$975.15M	N/A	N/A	100
DNLI Denali Therapeutics	3.3042 of 5 stars	$27.21 +1.9%	$34.25 +25.9%	+82.4%	$4.24B	$330.53M	N/A	430	News Coverage Analyst Forecast
NAMS NewAmsterdam Pharma	3.5739 of 5 stars	$35.92 +0.3%	$49.00 +36.4%	+54.5%	$4.19B	$22.50M	N/A	4	News Coverage Positive News
DYN Dyne Therapeutics	3.2305 of 5 stars	$24.27 +1.8%	$34.17 +40.8%	+173.6%	$3.94B	N/A	N/A	100
TLX Telix Pharmaceuticals	4.5914 of 5 stars	$11.78 +2.0%	$21.00 +78.3%	-31.3%	$3.92B	$803.79M	N/A	1,184	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLDB) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solid Biosciences (SLDB) Competitors

SLDB vs. DNLI, NAMS, DYN, TLX, and GPCR

How does Solid Biosciences compare to Denali Therapeutics?

Summary

How does Solid Biosciences compare to NewAmsterdam Pharma?

Summary

How does Solid Biosciences compare to Dyne Therapeutics?

Summary

How does Solid Biosciences compare to Telix Pharmaceuticals?

Summary

How does Solid Biosciences compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solid Biosciences (SLDB) Competitors

SLDB vs. DNLI, NAMS, DYN, TLX, and GPCR

How does Solid Biosciences compare to Denali Therapeutics?

Which has more risk and volatility, SLDB or DNLI?

Do institutionals and insiders believe in SLDB or DNLI?

Is SLDB or DNLI more profitable?

Which has better valuation & earnings, SLDB or DNLI?

Does the media prefer SLDB or DNLI?

Do analysts prefer SLDB or DNLI?

Summary

How does Solid Biosciences compare to NewAmsterdam Pharma?

Do analysts recommend NAMS or SLDB?

Which has more risk & volatility, NAMS or SLDB?

Do institutionals and insiders believe in NAMS or SLDB?

Which has preferable earnings and valuation, NAMS or SLDB?

Is NAMS or SLDB more profitable?

Does the media refer more to NAMS or SLDB?

Summary

How does Solid Biosciences compare to Dyne Therapeutics?

Which has better valuation & earnings, DYN or SLDB?

Which has more volatility & risk, DYN or SLDB?

Does the media prefer DYN or SLDB?

Do insiders and institutionals hold more shares of DYN or SLDB?

Is DYN or SLDB more profitable?

Do analysts recommend DYN or SLDB?

Summary

How does Solid Biosciences compare to Telix Pharmaceuticals?

Do analysts recommend TLX or SLDB?

Is TLX or SLDB more profitable?

Do insiders and institutionals believe in TLX or SLDB?

Which has more risk and volatility, TLX or SLDB?

Which has higher valuation & earnings, TLX or SLDB?

Does the media prefer TLX or SLDB?

Summary

How does Solid Biosciences compare to Structure Therapeutics?

Which has stronger earnings & valuation, GPCR or SLDB?

Is GPCR or SLDB more profitable?

Do analysts prefer GPCR or SLDB?

Do insiders and institutionals have more ownership in GPCR or SLDB?

Which has more volatility & risk, GPCR or SLDB?

Does the media favor GPCR or SLDB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools